David Marek, Myovant
Myovant beefs up data package in NDA #3, boosting its case for longterm dosing of Pfizer-partnered relugolix
When Pfizer handed over $650 million in cash to partner on Myovant’s relugolix, the pharma giant made clear that the deal — valued at $4.2 billion total — was just as much about the approved indication of prostate cancer as the two women’s health conditions the drug could treat.
A month later, the two companies are offering another glimpse of the therapy’s longterm potential in endometriosis.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters